PCI in The Patient with Diabetes: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
Line 1: Line 1:
{{SI}}
{{SI}}
{{WikiDoc Cardiology Network Infobox}}
 
{{CMG}}
{{CMG}}



Latest revision as of 20:34, 4 September 2012

WikiDoc Resources for PCI in The Patient with Diabetes

Articles

Most recent articles on PCI in The Patient with Diabetes

Most cited articles on PCI in The Patient with Diabetes

Review articles on PCI in The Patient with Diabetes

Articles on PCI in The Patient with Diabetes in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on PCI in The Patient with Diabetes

Images of PCI in The Patient with Diabetes

Photos of PCI in The Patient with Diabetes

Podcasts & MP3s on PCI in The Patient with Diabetes

Videos on PCI in The Patient with Diabetes

Evidence Based Medicine

Cochrane Collaboration on PCI in The Patient with Diabetes

Bandolier on PCI in The Patient with Diabetes

TRIP on PCI in The Patient with Diabetes

Clinical Trials

Ongoing Trials on PCI in The Patient with Diabetes at Clinical Trials.gov

Trial results on PCI in The Patient with Diabetes

Clinical Trials on PCI in The Patient with Diabetes at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on PCI in The Patient with Diabetes

NICE Guidance on PCI in The Patient with Diabetes

NHS PRODIGY Guidance

FDA on PCI in The Patient with Diabetes

CDC on PCI in The Patient with Diabetes

Books

Books on PCI in The Patient with Diabetes

News

PCI in The Patient with Diabetes in the news

Be alerted to news on PCI in The Patient with Diabetes

News trends on PCI in The Patient with Diabetes

Commentary

Blogs on PCI in The Patient with Diabetes

Definitions

Definitions of PCI in The Patient with Diabetes

Patient Resources / Community

Patient resources on PCI in The Patient with Diabetes

Discussion groups on PCI in The Patient with Diabetes

Patient Handouts on PCI in The Patient with Diabetes

Directions to Hospitals Treating PCI in The Patient with Diabetes

Risk calculators and risk factors for PCI in The Patient with Diabetes

Healthcare Provider Resources

Symptoms of PCI in The Patient with Diabetes

Causes & Risk Factors for PCI in The Patient with Diabetes

Diagnostic studies for PCI in The Patient with Diabetes

Treatment of PCI in The Patient with Diabetes

Continuing Medical Education (CME)

CME Programs on PCI in The Patient with Diabetes

International

PCI in The Patient with Diabetes en Espanol

PCI in The Patient with Diabetes en Francais

Business

PCI in The Patient with Diabetes in the Marketplace

Patents on PCI in The Patient with Diabetes

Experimental / Informatics

List of terms related to PCI in The Patient with Diabetes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



Diagnostic Cardiac Catheterization in the Patient with Diabetes

PCI in the patient with Diabetes

The DIABETES trial was the first randomized multicenter trial examining the efficacy of SES in preventing restenosis in diabetic patients. The trial randomized 160 diabetic patients with de novo coronary stenoses to either SES or BMS. One year dual antiplatelet therapy of aspirin and clopidogrel was routinely prescribed for one year in both arms.

The DIABETES (DIABETes and sirolimus Eluting Stent) trial showed a marked reduction in target lesion revascularization (TLR) with the sirolimus-eluting stent (SES) compared with the bare metal stent (BMS) at 2 year follow-up. However, there was also a significant cumulative rate of revascularization due to atherosclerosis progression in both groups as well as an increase in late stent thrombosis after clopidogrel discontinuation.

The overall MACE rate, defined as death, MI, TLR, or stent thrombosis, was significantly lower in the SES group at the two year follow-up, though this was driven by the considerable reduction in the TLR rate after SES implantation. At the two year follow-up, the rate of TLR was 7.7% in the SES group compared with 35.0% in the BMS group (p<0.001). There were no significant differences in the rates of death or MI between the groups.

The total revascularization rate at two years increased in both the SES and BMS groups (7.7%and 10% respectively; p=0.7) due to progression of atherosclerosis in segments remote from the target lesion.

The beneficial effect of SES implantation in clinical restenosis was independent of diabetes treatment, gender, vessel location, the use of IIb/IIIa inhibitors, stent size, and reference vessel diameter.

Read the news brief of this trial in the WikiDoc News section

PCI in Diabetic Ketoacidosis

Template:WikiDoc Sources Template:Mdr